<DOC>
	<DOCNO>NCT00564187</DOCNO>
	<brief_summary>Primary : - To evaluate efficacy two regimen irbesartan patient respond normalized 6 week treatment ( schema N°1 : maintenance 150 mg/day , schema n°2 : 300 mg/day 6 week ) Secondary : - To evaluate percentage patient DBP &lt; 90 mmHg 6 12 week - To evaluate percentage patient SBP &lt; 140 mmHg 6 12 week - To evaluate rate adverse event study</brief_summary>
	<brief_title>Evaluation Efficacy Safety Dosage Adjustment Aprovel® ( Irbesartan ) Hypertensive Outpatients Current Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Mild Moderate hypertension ( 90mmHg &lt; DBP &lt; 110mmHg 140mmHg &lt; SBP &lt; 180mmHg ) Or new diagnose hypertension ( 2 visit within 1 month ) , never treat respond required condition treatment irbesartan , adapt insufficient diet Or patient already treat nonsatisfying antihypertensive treatment stop since least 2 week inclusion A minimum exam lab require WHOISH within month inclusion Severe Arterial Hypertension ( PAS &gt; = 180 mm Hg PAD &gt; = 110 mmHg ) Isolated Systolic Hypertension Secondary Hypertension Bilateral renal arterial stenosis renal arterial stenosis Non surgically sterilise woman non postmenopausal woman Confirmed sodium depletion Irbesartan hypersensitivity The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>